RT Journal Article
SR Electronic
T1 Feasibility and acceptability of collecting dried blood spots (DBS) from children after vaccination during Supplementary Immunization Activities to estimate measles and rubella seroprevalence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.14.24302830
DO 10.1101/2024.02.14.24302830
A1 Carcelen, Andrea C.
A1 Prosperi, Christine
A1 Hamahuwa, Mutinta
A1 Kapungu, Kelvin
A1 Chongwe, Gershom
A1 Mwansa, Francis D.
A1 Ndubani, Phillimon
A1 Simulundu, Edgar
A1 Bwalya, Innocent C.
A1 Matakala, Kalumbu H.
A1 Musukwa, Gloria
A1 Mutale, Irene
A1 Betha, Evans
A1 Chaavwa, Nchimunya
A1 Kampamba, Lombe
A1 Matoba, Japhet
A1 Munachoonga, Passwell
A1 Mufwambi, Webster
A1 Situtu, Ken
A1 Thuma, Philip E.
A1 Sakala, Constance
A1 Kayeye, Princess
A1 Truelove, Shaun A.
A1 Winter, Amy K.
A1 Ferrari, Matthew J
A1 Moss, William J.
A1 Mutembo, Simon
YR 2024
UL http://medrxiv.org/content/early/2024/02/15/2024.02.14.24302830.abstract
AB Nested serosurveys within routine service delivery platforms such as planned supplemental immunization activities (SIAs) provide an opportunity to collect information that can be used to answer valuable questions on the effectiveness and efficiency of the delivery model to inform future activities. However, integrating research data collection in SIAs is rarely done due to concerns it will negatively impact the program.We conducted a serosurvey nested within the November 2020 measles-rubella SIA integrated with the Child Health Week activities in Zambia to evaluate this approach. In-depth interviews with the study teams and vaccination campaign staff at the vaccination sites were conducted. Recorded interviews were transcribed, transcripts were coded and then grouped into themes based on a process evaluation framework. A multi-methods analytical approach was used to assess the feasibility and acceptability of collecting dried blood spots from children during the SIA. This included a quantitative assessment of participant enrollment.The serosurvey successfully enrolled 90% of children from Child Health Week due to close coordination and teamwork between the vaccination teams and serosurvey team, in addition to substantial social mobilization efforts. Continually adjusting the sampling interval that was used to select eligible children allowed us to enroll throughout the SIA and capture a representative sample of children in attendance although it was challenging for the staff involved.As vaccination programs aim to tailor their approaches to reach the hardest-to-reach children, embedding research questions in SIAs will allow evaluation of the successes and challenges and compare alternative approaches. Lessons learned from this experience collecting data during an SIA can be applicable to future research activities embedded in SIAs or other delivery platforms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Strengthening Immunization Systems through Serosurveillance grant (grant number 1094816) from The Bill & Melinda Gates Foundation to the International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Tropical Diseases Research Centre ethics review committee, and Johns Hopkins Bloomberg School of Public Health Institutional Review Board. Further regulatory approval was given by the Zambia National Health Research Authority. Written consent was obtained from caregivers before enrolment in the serosurvey and for in-depth interviews of health workers verbal consent was obtained from serosurvey staff and vaccinators.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes